A Japanese case series reports that ensitrelvir (an oral antiviral) rescued three men with follicular lymphoma who had persistent COVID-19 that did not respond to remdesivir. After ensitrelvir treatment, patients improved despite remdesivir-refractory viral persistence. While the report is small and observational, it directly informs clinical decision-making for immunocompromised oncology patients where standard antiviral sequences may fail. It also highlights the practical value of next-line oral antivirals in settings dominated by constrained immune responses. For developers and clinicians, the key takeaway is the feasibility of switching antiviral mechanisms when viral control does not occur, particularly in patients receiving anti-CD20 therapy.